Founded in 2004, Solstice Neurosciences, Inc. is a biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty products. Solstice's first product, MYOBLOC, represents the only botulinum toxin type B currently available to physicians and patients worldwide. MYOBLOC is sold in the United States and is approved in Canada. It is also distributed and sold in the EU as NeuroBloc. Solstice recently received approval for promotion of botulinum toxin type B in South Korea.
View Top Employees from Solstice Neurosciences , Inc.| Website | http://www.solsticeneuro.com |
| Revenue | $14 million |
| Employees | View employees |
| Founded | 2003 |
| Address | 40 General Warren Blvd, Ste 160, Malvern, Pennsylvania 19355, US |
| Phone | (267) 620-8000 |
| Industry | Pharmaceuticals, Drug Manufacturing & Research, Biotechnology, Science and Engineering, Colleges & Universities, Manufacturing, Education, Marketing, Healthcare, Sales and Marketing |
| Competitors | AEterna Zentaris Inc., Allena Pharmaceuticals, Inc., Amarillo Biosciences Inc, Mereo BioPharma, QOL Medical LLC |
| SIC | SIC Code 82 Companies, SIC Code 822 Companies |
| NAICS | NAICS Code 611 Companies, NAICS Code 61131 Companies, NAICS Code 6113 Companies, NAICS Code 611310 Companies, NAICS Code 61 Companies |
Looking for a particular Solstice Neurosciences , Inc. employee's phone or email?
Solstice Neurosciences , Inc. Questions
The Solstice Neurosciences , Inc. annual revenue was $14 million in 2023.
Solstice Neurosciences , Inc. is based in Malvern, Pennsylvania.
The NAICS codes for Solstice Neurosciences , Inc. are [611, 61131, 6113, 611310, 61].
The SIC codes for Solstice Neurosciences , Inc. are [82, 822].
